An an­tibi­otics biotech be­gins wind-down, lays off near­ly all work­ers

An an­tibi­otics biotech is about to throw in the tow­el, deal­ing an­oth­er blow to a sparse R&D field and rais­ing red flags in the light of an­timi­cro­bial re­sis­tance.

Nabri­va Ther­a­peu­tics, which has been soul search­ing for the past two months with an ad­vi­sor, is lay­ing off near­ly all its em­ploy­ees, re­turn­ing the pro­mo­tion and dis­tri­b­u­tion rights of an an­tibac­te­r­i­al to Mer­ck, can­cel­ing a loan agree­ment and mak­ing oth­er moves to “ad­e­quate­ly fund an or­der­ly wind down of the Com­pa­ny’s op­er­a­tions.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER